Amneal Lines Up Ready-To-Use Pemetrexed Hybrid

Q1 2024 Launch Planned After FDA Approval For Pemrydi 505(b)(2) Oncology Injectable

Amneal has set a launch date for its ready-to-use presentation of pemetrexed after the FDA approved the 505(b)(2) product under the name of Pemrydi.

Amneal
The FDA has approved Amneal’s Pemrydi RTU

Amneal says it is planning an early 2024 launch for its Pemrydi (pemetrexed) ready-to-use oncology injectable after the US Food and Drug Administration approved the product via the 505(b)(2) hybrid pathway.

Describing Pemrydi as “the first ready-to-use presentation of [this] key injectable,” Amneal said the product was indicated, in combination with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin